Background and aims Liver failure syndromes are characterized by a dysregulated immune response leading to immune paralysis.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Enforcement of universal screenings would easily prevent sickness, expenses and death but enforcement isn’t easy.

Serious infections significantly increase the mortality risk among adults with chronic liver disease, including those without cirrhosis.

GAAP loss per share of ($0.12) in Q2 2025 beat expectations, driven by a sharp drop in research and development costs. No revenue reported, reflecting ongoing clinical-stage operations and focus on ...

Pooled data show that no or shorter antibiotic prophylaxis for upper GI bleeding in cirrhosis is very likely noninferior to longer courses for all-cause mortality, challenging long-standing advice.

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...